LumiThera
Robert J. Bard is a consultant, acting Vice President of Quality and Regulatory Affairs at LumiThera. Prior to LumiThera, Mr. Bard has been the Managing Director at HealthCare Technologies Consultants LLC, the Vice President of Regulatory and Quality Systems at Sciele Pharma and the Vice President of Regulatory and Clinical Affairs and Quality Assurance at Aastrom Biosciences. Mr. Bard has 42 years of compliance, ethics, legal and regulatory affairs, quality control, quality assurance, clinical affairs and development, and manufacturing and operations experience in pharmaceuticals, devices, biotech and biologics industries. Therapeutic areas include ophthalmology, hematology, orthopedics, infusion therapy and pain management, neurology, oncology, dermatology, regenerative medicine and monoclonal antibiotic therapeutics. Mr. Bard earned a Bachelor of Science in Microbiology from the University of California (Los Angeles) and a Juris Doctorate from American College of Law. Mr. Bard is a member of the California Bar and is certified as a Regulatory Professional by the Regulatory Affairs Professional Society and a Certified Quality Engineer by the American Society for Quality.
This person is not in any offices
LumiThera
1 followers
At LumiThera, they are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. They will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company’s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area.